Last reviewed · How we verify
Paclitaxel Lipid Suspension
Paclitaxel Lipid Suspension is a Taxane Small molecule drug developed by Jina Pharmaceuticals Inc.. It is currently in Phase 3 development for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of ovarian cancer, Adjuvant treatment of non-small cell lung cancer.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of ovarian cancer, Adjuvant treatment of non-small cell lung cancer.
At a glance
| Generic name | Paclitaxel Lipid Suspension |
|---|---|
| Sponsor | Jina Pharmaceuticals Inc. |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to tubulin, a protein that makes up microtubules, and prevents them from disassembling. This leads to the formation of stable microtubules that prevent cell division, ultimately causing cell death. This mechanism is particularly effective against rapidly dividing cancer cells.
Approved indications
- Adjuvant treatment of node-positive breast cancer
- Adjuvant treatment of ovarian cancer
- Adjuvant treatment of non-small cell lung cancer
- Treatment of AIDS-related Kaposi's sarcoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Mucositis
- Diarrhea
- Nausea
- Vomiting
- Alopecia
- Arthralgia
Key clinical trials
- Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel Lipid Suspension CI brief — competitive landscape report
- Paclitaxel Lipid Suspension updates RSS · CI watch RSS
- Jina Pharmaceuticals Inc. portfolio CI
Frequently asked questions about Paclitaxel Lipid Suspension
What is Paclitaxel Lipid Suspension?
How does Paclitaxel Lipid Suspension work?
What is Paclitaxel Lipid Suspension used for?
Who makes Paclitaxel Lipid Suspension?
What drug class is Paclitaxel Lipid Suspension in?
What development phase is Paclitaxel Lipid Suspension in?
What are the side effects of Paclitaxel Lipid Suspension?
What does Paclitaxel Lipid Suspension target?
Related
- Drug class: All Taxane drugs
- Target: All drugs targeting Microtubules
- Manufacturer: Jina Pharmaceuticals Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of node-positive breast cancer
- Indication: Drugs for Adjuvant treatment of ovarian cancer
- Indication: Drugs for Adjuvant treatment of non-small cell lung cancer
- Compare: Paclitaxel Lipid Suspension vs similar drugs
- Pricing: Paclitaxel Lipid Suspension cost, discount & access